An Open-Label, Randomized, Single-Dose Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
56
Yangji Hospital
Seoul, South Korea
Cmax of Losartan
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
AUClast of Losartan
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
Cmax of EXP3174
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
AUClast of EXP3174
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
Cmax of Chlorthalidone
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~144hours
AUClast of Chlorthalidone
Pharmacokinetic evaluation
Time frame: Day 1, Day 15:pre-dose(0 hour)~144hours
AUC inf, Tmax, T1/2, Cl/F, Vd/F of Losartan
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
AUC inf, Tmax, T1/2, Cl/F, Vd/F of EXP3174
Pharmacokinetic evaluation
Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
AUC inf, Tmax, T1/2, Cl/F, Vd/F of Chlorthalidone
Pharmacokinetic evaluation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 1, Day 15:pre-dose(0 hour)~144hours